Last reviewed · How we verify
ACT-20-CM
At a glance
| Generic name | ACT-20-CM |
|---|---|
| Sponsor | Aspire Health Science |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ACT-20 in Patients With Severe COVID-19 Pneumonia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACT-20-CM CI brief — competitive landscape report
- ACT-20-CM updates RSS · CI watch RSS
- Aspire Health Science portfolio CI